Institutional Trading Alert for Johnson & Johnson
Posted on 02/26/2015 by Edward Connelly
A total of 22 block trades were executed today, typically at least 10,000 shares or more represent a single block unit. Block trades help investors understand the sentiment of large financial institutions. Further trading analysis reveals that 553.59K shares were bought and 224.81K shares were sold. The bought/sold ratio for shares of Johnson & Johnson is 2.46, representing a positive net cash flow of $33,681,888 into the stock.
A deeper look into options trading also reveals that traders hedged their positions with options where 7.59K put and 22.29K call contracts exchanged hands leading to a 0.34 put/call ratio.
Johnson & Johnson ranks as the world's largest and most diverse health-care company. The company comprises three divisions: pharmaceutical, medical devices and diagnostics, and consumer. While the pharmaceutical division currently represents close to 36% of total sales, we expect patent losses and the Synthes acquisition to reduce this proportion to approximately 27% during the next 10 years, with the device segment picking up the majority of the share.
Johnson & Johnson settled the day up $1.59 to $102.80 in the previous trading session. Today's trading range was between $101.22 and $103.18 respectively. On the volume side, 11.18M shares were traded, which is greater than the average volume of 10.44M shares. JNJ is trading above the fifty day moving average and higher than the two hundred day moving average. The stock's 52 week low is $90.75 and 52 week high is $109.49. Within the last quarter, the shares have lost -5.51% of their value. The technical momentum Relative Strength Index indicator shows oversold conditions. The stock has a P/E ratio of 18.03 and a dividend yield of 0.70%.
Sentiment: Strong Buy
Outside the US, levosimendan is approved and marketed under the trade name of Simdax (levosimendan i.v.) in over 50 countries for use in Acute Decompensated Heart Failure. Over 800,000 patients have been prescribed the drug from its launch in early 2000.
Mechanism of Action
Levosimendan is a novel, first in class calcium sensitizer/K-ATP activator. The therapeutic effects of levosimendan are mediated through:
•increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect which is not associated with substantial increases in oxygen demand (3).
•opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds (4).
•opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect (5)
Low Cardiac Output Syndrome:Definition and Incidence
LCOS is generally defined as a patient’s inability to maintain a cardiac index 2.2 L/min/m2 and hence requiring use of inotropic agents and/or mechanical assist devices such as an intra aortic balloon pump or a left ventricular assistance device. LCOS in the cardiac surgery setting is reported to occur in 5-10% of patients undergoing cardiac surgery and is associated with 10-15 fold higher mortality or severe sequelae as a result of poor organ perfusion (eg. kidney failure, end stage renal disease [ESRD]) (6),(7),(8),(9) (10).
Post-cardiotomy LCOS is associated with poor outcomes including a 10- to 15-fold increase in operative mortality (9).
Unmet Medical Need
Currently no pharmacologic therapies are approved for management or prevention of post-cardiotomy LCOS. While conventional inotropes are used to manage cardiac hemodynamics in the peri-operative setting, none have been shown to improve outcomes.
Did the U.S. Goverment Just Ensure Success for Apple Inc Pay?
By Daniel B. Kline | More Articles
February 22, 2015 | Comments (0)
The Obama administration has given Apple (NASDAQ: AAPL ) Pay the presidential seal of approval.
The White House announced earlier this month that Apple Pay will join EMV chip-and-PIN as a standard for the roughly 9 million federal payment cards, including debit card accounts, used for distributing Social Security and veterans benefits. Apple Pay allows people to make financial transactions using credit or debit card information stored on an iPhone or iPad.
A press release from the White House detailed the steps taken: "Apple, Visa, MasterCard, Comerica Bank, and U.S. Bank are committed to working together to make Apple Pay, a tokenized, encrypted service, available for users of federal payment cards, including DirectExpress and GSA SmartPay cards."
Apple Pay will also be accepted starting in September for some government transactions, CEO Tim Cook said on Feb. 13th while speaking at the White House Summit on Cybersecurity and Consumer Protection.
These moves put Apple Pay on increasingly equal footing with traditional payment methods and should help the product gain traction.
What does this mean?
Allowing use of Apple Pay in government payments opens up a huge pool of business for the company. It could also serve as a litmus test to whether the general public will embrace mobile payments.
"Tech and financial industries are hoping mobile payments will be the next big thing, but consumers really haven't seemed too interested so far," said Newsy's Zach Toombs in a video posted at USA Today. "So, there will likely be a lot of focus as to whether people embrace Apple Pay through the federal government."
Once the new option is launched, Apple Pay will be an option for people receiving Social Security, veterans benefits, and other government money in lieu of the current system of prepaid debit cards. The opportunity for Apple, wh
Sentiment: Strong Buy
Let's hope it happens after the first of the year.
Mako gets a little Wall Street love by extending its robotic arms into total hip replacements
September 19, 2011 by MassDevice staff
Mako officially launches its robotic surgical system for use in total hip replacement procedures, winning a bump for share prices and a pat on the back from investment analysts.
Mako Surgical Corp.'s (NSDQ:MAKO) commercial launch of the RIO surgical robotic arm for hip replacement surgery won some love from analysts and investors on Wall Street today.
Shares jumped 7 percent to $38.76 in mid-day trading, after closing at $36.27 Friday, with analysts at Leerink Swann noting that MAKO shares are outperforming the market today.
The device helps surgeons more accurately align and position implants based on a pre-operation three-dimensional model of the patient's hip. The robotic arm also assists the surgeon in preparing the joint and placing the hip implant.
The device was cleared for use in February 2010, according to a press release, and has been available for surgical treatment of osteoarthritis of the knee for 5 years.
"Mako's robotic hip solution has the potential to open up significant incremental revenue opportunities," wrote Leerink analysts Rick Wise and Richard Newitter. "The total hip arthroplasty market is much bigger than the market for partial knee replacements."
"Mako's platform, until today, only targeted uni- and bi-compartmental knee procedures. We estimate the [worldwide] hip market represents a $5-6B opportunity," the analysts wrote.
About 10 million Americans suffer from osteoarthritis of the hip, a wearing away of the cartilage that cushions the bones, causing pain and stiffness that can affect mobility. About half of the acetabular cups used in hip replacements are implanted improperly, which can lead to dislocation, fracture and increased wear on the implants, according to a study cited by Mako Surgical.
The RIO system may have a tough battle ahead. Sunnyvale, Calif.-based Intuitive Surgical Inc. (NSDQ:ISRG), a Zacks Investment Research favorite, has virtually cornered the market on robotic surgery.
Precisely why I don't use stops. They are like hanging fruit for the MMs to get. They will drop the price just to steal your shares.